<DOC>
	<DOC>NCT01728363</DOC>
	<brief_summary>Multiple center, open-label, PK study</brief_summary>
	<brief_title>Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)</brief_title>
	<detailed_description>Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics in hospitalized infants with suspected systemic infection or receiving one of the study drugs per local standard of care. Number of participants are 16-32 evaluable per each study drug of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics.</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Ticarcillin-clavulanic acid</mesh_term>
	<mesh_term>Ticarcillin</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Sufficient intravascular access Suspected systemic infection or receiving 1 of the study drugs per standard of care informed consent from legal guardian history of allergic reaction to study drugs urine output &lt;0.5 mL/hr/kg over the prior 24 hours serum creatinine &gt;1.7 mg/dl Any condition in investigator judgment precludes participation because it could affect participant safety</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Staphylococcal</keyword>
</DOC>